PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.60
Bid: 5.40
Ask: 5.75
Change: 0.67 (13.59%)
Spread: 0.35 (6.481%)
Open: 4.78
High: 5.60
Low: 4.78
Prev. Close: 4.93
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Technology Update

6 Jun 2017 07:00

RNS Number : 2009H
Plant Health Care PLC
06 June 2017
 

6 June 2017

Plant Health Care plc(the "Company" ", "PHC" or "Plant Health Care")New Technology Update

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

- Evaluation of Innatus 3G continues to expand. The four major industry partners have increased the scale of their 2017 trials. Three other companies have signed evaluation agreements and are conducting field trials.

- A total of eight agreements have also now been signed concerning T-Rex 3G and Y-Max-3G.

- Strong progress continues within Plant Health Care on its capability to make, formulate and register PREtec peptides.

- The Company remains on track to deliver a revenue-generating licence by the end of 2017 and the first competitive licensing process in early 2018.

 

Innatus 3G

Four of the top six agrochemicals companies have been evaluating Innatus 3G since 2015. They are focused on three core agricultural benefits - yield increase, disease and nematode protection and drought resistance - mainly in the largest commercial crops corn (maize) and soybean. Building on their 2016 results, all are running trials of lead peptides from this platform in 2017.

By early 2017, three other companies had signed agreements to evaluate Innatus 3G. Their field trials, in other smaller crops, are underway in Europe and South America.

In recent weeks several partners have approached PHC with plans to expand their 2017 trials further. Of particular interest is the control of Asian Soybean Rust, a fungal disease which is a major threat to the soybean crop in Brazil. This disease has developed resistance to most conventional fungicides. Innatus 3G peptides work very differently, and when sprayed in mixtures with standard fungicides, they have shown significantly improved disease control in PHC's trials. This has the potential to increase the effectiveness and extend the commercial life of those established products.

T-Rex 3G and Y-Max 3G

PHC's new technology platforms, T-Rex 3G and Y-Max 3G, were first presented to the industry in 2016. T-Rex 3G is a class of signal peptides optimised for nematode suppression, while Y-Max 3G peptides are biostimulants which increase yield.

A total of eight companies have so far signed up to evaluate one or both of these new platforms, including the majors who are evaluating Innatus 3G. Trials are in progress in three continents in a range of crops, with two lead peptides from each of T-Rex 3G and Y-Max 3G. The majors are focused mainly on corn and soybean, while others are working on a wider range of crops.

The Company continues to aim to secure the first revenue-generating licence of one of its PREtec technologies in 2017.

PHC's product development capability

Plant Health Care has increased its product development activity. This includes substantially expanding its own 2017 field trials and contract testing programme. But because partners' evaluations of PREtec peptides are on a much larger scale than in 2016, collectively they are spending many times more than the Company is.

Plant Health Care's work on the physical stability of peptides in formulations and their compatibility with agrochemicals continues to show promising results. We expect the most cost-effective means of peptide manufacture to be by fermentation, and laboratory scale production trials are on track. The first lead peptides produced by fermentation are being evaluated and will shortly be entering field trials.

 

Chris Richards, Executive Chairman & Interim CEO, said "Momentum continues to build. As we approach the expected 2018 date for licensing of first rights to Innatus 3G, partners are stepping up their evaluations. Our lead peptides from each platform are performing well in independent trials, carried out by our partners."

"It is a great vote of confidence in our proprietary technology. Every one of our initial partners is now testing one or both of T-Rex 3G and Y-Max 3G, alongside Innatus 3G. Our new partners are expanding the range of crops to which our products can bring benefits. This year, partners will spend much more than us on evaluating our proprietary technology."

"We are well positioned for the first licensing of our PREtec technology by the end of 2017, with competitive licensing of Innatus 3G to start in early 2018."

 

Enquiries:

Plant Health Care plc

Dr Chris Richards, Executive Chairman and Interim CEO

Tel: +44 (0) 18 3788 0083

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke

Tel: +44 (0) 20 3100 2000

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESUGUWCQUPMGMA
Date   Source Headline
30th Apr 200811:24 amRNSTotal Voting Rights
28th Apr 20088:09 amRNSNew Trials
14th Apr 20085:39 pmRNSDirector/PDMR Shareholding
2nd Apr 20086:18 pmRNSDirector/PDMR Shareholding
1st Apr 20087:01 amRNSDirectorate Change
1st Apr 20087:01 amRNSTotal Voting Rights
31st Mar 20087:02 amRNSFinal Results
12th Mar 20084:40 pmRNSAdditional Listing
29th Feb 20084:59 pmRNSTotal Voting Rights
21st Feb 20087:01 amRNSStatement re Monsanto
18th Feb 20088:00 amRNSASA Partnership
12th Feb 20085:14 pmRNSAdditional Listing
31st Jan 20084:03 pmRNSTotal Voting Rights
21st Jan 20087:01 amRNSRe Agreement
21st Jan 20087:01 amRNSProduct Update
21st Jan 20087:01 amRNSTrading Statement
14th Jan 200811:57 amRNSNotification of Shareholding
9th Jan 20089:00 amRNSField Trial Update
31st Dec 200712:51 pmRNSTotal Voting Rights
19th Dec 20079:00 amRNSNotification of Shareholding
3rd Dec 20073:00 pmRNSTotal Voting Rights
20th Nov 20079:15 amRNSAdditional Listing
1st Nov 200712:16 pmRNSTotal Voting Rights
24th Oct 20076:13 pmRNSStock Award
22nd Oct 200710:35 amRNSNotification of Shareholding
5th Oct 20073:56 pmRNSNotification of Shareholding
2nd Oct 20074:46 pmRNSNotification of Shareholding
2nd Oct 200712:59 pmRNSTotal Voting Rights
1st Oct 20075:54 pmRNSNotification of Shareholding
1st Oct 20075:51 pmRNSNotification of Shareholding
1st Oct 20073:22 pmRNSDoc re. Interim Results
27th Sep 20075:19 pmRNSDirector/PDMR Shareholding
27th Sep 20077:01 amRNSPlacing
24th Sep 20077:03 amRNSHalf Year Results
24th Sep 20077:02 amRNSMyconate Trial Results
31st Aug 200710:14 amRNSTotal Voting Rights
28th Aug 20071:00 pmRNSStock Award
23rd Aug 200710:14 amRNSNotice of Results
13th Aug 20074:15 pmRNSAIM Rule 26 Information
13th Aug 200711:55 amRNSHolding(s) in Company
13th Aug 20078:49 amRNSHolding(s) in Company
31st Jul 200711:39 amRNSTotal Voting Rights
27th Jul 20077:01 amRNSN-Hibit Trial Results
25th Jul 20071:38 pmRNSAdditional Listing
23rd Jul 200711:35 amRNSDirector/PDMR Shareholding
2nd Jul 20072:25 pmRNSTotal Voting Rights
27th Jun 20077:01 amRNSProduct Update
11th Jun 20075:53 pmRNSHolding(s) in Company
8th Jun 20075:03 pmRNSAGM Statement
4th Jun 20077:31 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.